US 11464802
3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
granted A61KA61K2039/5152A61K2239/49
Quick answer
US patent 11464802 (3-substituted piperidine compounds for Cbl-b inhibition, and use thereof) held by NURIX THERAPEUTICS, INC. expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- NURIX THERAPEUTICS, INC.
- Grant date
- Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 53
- CPC classes
- A61K, A61K2039/5152, A61K2239/49, A61K2239/50, A61K2239/55